Saxenda vs Victoza
Change comparisonThese brands contain liraglutide. Compare their approved uses, formulations, and self-pay prices. Products are not interchangeable.
| Compare | Saxenda | Victoza |
|---|---|---|
| Active ingredient | LiraglutideGLP-1 | LiraglutideGLP-1 |
| How it is taken | Injection Once daily | Injection Once daily |
| Manufacturer | Novo Nordisk | Novo Nordisk |
What was actually compared
No direct trial comparing these exact brands is included in our reviewed catalog. Sharing an ingredient does not establish the same outcomes at different doses or formulations.
Weight-loss results by formulation
Each result belongs to its named trial and dose. Separate trials have different participants and methods; these figures are not a direct comparison.
| Compare | Saxenda | Victoza |
|---|---|---|
| Injection evidence | −8% (-8.0% at 56 wks · SCALE Obesity · 3.0 mg daily (Saxenda)) SCALE Obesity · -8.0% at 56 wks 3.0 mg daily (Saxenda) Analysis not classified; see trial methods | No reviewed weight-loss result for this brand and formulation. |
Entry price and maintenance price
Self-pay quotes, not insurance estimates. Each figure identifies the product, provider, and dose where published.
| Compare | Saxenda | Victoza |
|---|---|---|
| Injection prices | Advertised entry price No product-specific quote tracked. Published maintenance dose No dose-specific quote tracked. | Advertised entry price No product-specific quote tracked. Published maintenance dose No dose-specific quote tracked. |
How these quotes are selected
For each price basis, we prefer a recently checked manufacturer-direct quote, then a recently checked provider quote for that brand and formulation. Within each group, documented 30-day costs come first, lowest to highest. Quotes without a documented supply period have no cost rank. Older quotes appear as dated references only when no current quote is tracked. Providers may differ between entry and maintenance prices. Missing maintenance prices are never replaced with entry prices. Compounded products, combined brand quotes, and membership-only fees are excluded. Prices at different doses are not equivalent treatment costs; confirm supply length, eligibility, and added fees.
Every cash quote was checked on or after . Each quote shows its own check date. A quoted maintenance dose is not a dosing recommendation. Our methodology
Approved uses by formulation
Eligibility, contraindications, and warnings are in each product's full prescribing information.
| Compare | Saxenda | Victoza |
|---|---|---|
| Injection | Weight management in adults and children 12+ with obesity and body weight over 60 kg; adults with overweight and a weight-related condition. US prescribing information (Saxenda Injection prescribing information)Reviewed Sep 22, 2026 | Glucose control in adults and children 10+ with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease. US prescribing information (Victoza Injection prescribing information)Reviewed Sep 22, 2026 |